FR2778847A1 - Implants for sub-gingival injection comprising bio-resorbable microspheres containing an antiseptic or antibiotic - Google Patents

Implants for sub-gingival injection comprising bio-resorbable microspheres containing an antiseptic or antibiotic Download PDF

Info

Publication number
FR2778847A1
FR2778847A1 FR9806415A FR9806415A FR2778847A1 FR 2778847 A1 FR2778847 A1 FR 2778847A1 FR 9806415 A FR9806415 A FR 9806415A FR 9806415 A FR9806415 A FR 9806415A FR 2778847 A1 FR2778847 A1 FR 2778847A1
Authority
FR
France
Prior art keywords
microspheres
gel
implant according
bio
gauge
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
FR9806415A
Other languages
French (fr)
Inventor
Jean Pierre Perraud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to FR9806415A priority Critical patent/FR2778847A1/en
Publication of FR2778847A1 publication Critical patent/FR2778847A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0063—Periodont
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/06—Flowable or injectable implant compositions

Abstract

An implant for sub-gingival injection comprising bio-resorbable microspheres suspended in a physiological gel.- DETAILED DESCRIPTION - The microspheres are made from a lactic-glycolic copolymer and poly(D,L-lactide coglycolide) copolymer, Resomer RG 502 and RG 756 (RTM). Crystalline polylactic acid may also be used. The physiological gel is either 0.8% hyaluronic acid or its sodium salt, or 5% colloidal silica. The composition may contain 5 - 40% by weight of the microspheres, especially 7 - 25%, these being bioresorbed in 6 months - 1 year. Their particle size is preferably 20 - 100 micro m, especially 50 micro m and the product is such that it will pass through a 26 - 30 gauge needle. The microspheres contain an antiseptic or antibiotic, that is released slowly as the microspheres biodegrade, typically hexetidine, propionic acid, chlorhexidine, hexamidine, macrolides, spiramycin, or metronidazole

Description

La présente invention concerne un implant injectable en sous gingivalThe present invention relates to an injectable subgingival implant

résorbable en un temps déterminé.  absorbable in a determined time.

Le domaine d 'utilisation de cet implant est la parodontologie et plus généralement tous les soins de chirurgie dentaire et le comblement des poches parodontales ou pyorées alvéo-dentaires L ' implant doit  The field of use of this implant is periodontology and more generally all dental surgery care and the filling of periodontal or alveo-dental pyorea pockets. The implant must

permettre la restructuration et la reconstruction du sillon gingival et de I 'at-  allow the restructuring and reconstruction of the gingival sulcus and the

tache épithéliale et. par son effet fibrosant, la mise en place d ' un faisceau de fibres secondaires en soutien du ligament parodontal et de la ligne amélo-cémentaire L 'implant pourra également colmater voire  epithelial spot and. by its fibrosing effect, the establishment of a bundle of secondary fibers in support of the periodontal ligament and the amelo-cementary line The implant may also clog or even

remplacer le cément.replace the cement.

L' implant injectable est constitué de microsphères bio-résorbables en une période de 6 mois à 1 an et en suspension dans un gel également bio-résorbable en 3 mois. Les microsphères contiennent un ou plusieurs principes actifs de type antiseptique: hexétidine acide propionique, chlorhexidine, hexamidine ou de type antibiotique: macrolides, spiramicine cycline, métronidazole. Le rôle des principes actifs de type antiseptique ou antibiotique est, en se libérant lentement au fur et à mesure de la bio-dégradation des microsphères, de stopper toute prolifération  The injectable implant consists of bio-absorbable microspheres in a period of 6 months to 1 year and suspended in a gel also bio-absorbable in 3 months. The microspheres contain one or more active principles of antiseptic type: hexetidine propionic acid, chlorhexidine, hexamidine or of antibiotic type: macrolides, spiramicin cyclin, metronidazole. The role of active principles of antiseptic or antibiotic type is, by slowly releasing as bio-degradation of the microspheres, to stop any proliferation

bactérienne et partant, de maintenir un environnement parodontal sain.  bacterial and hence to maintain a healthy periodontal environment.

La dégradation des microsphères de polymères biodégradables de type copolymére d ' acide lactique - co-glycolique ( PLGA) en milieu  Degradation of microspheres of biodegradable polymers of the lactic acid-co-glycolic acid (PLGA) type in medium

biologique se fait par un mécanisme chimique d ' hydrolyse non spécifique.  biological is done by a chemical mechanism of non specific hydrolysis.

Les produits de cette hydrolyse sont ensuite métabolisés puis catabolisés  The products of this hydrolysis are then metabolized and then catabolized

par le corps humain. L' hydrolyse chimique du PLGA est complète.  by the human body. The chemical hydrolysis of PLGA is complete.

Les matières premières entrant dans la préparation de cet implant appartiennent à la famille des bio-matériaux d ' origine végétale, minérale ou bio-génétique Les microsphères sont réalisees à partir de deux copolymères d ' acide lactique -co-glycolique (PLGA): Poly (D.L-Lactide-co glycolide) 50:50 Resomer' RG 502 et Poly (DL-Lactide- co-glycolide) 75:25  The raw materials used in the preparation of this implant belong to the family of bio-materials of plant, mineral or bio-genetic origin. The microspheres are made from two copolymers of lactic-co-glycolic acid (PLGA): Poly (DL-Lactide-co glycolide) 50:50 Resomer 'RG 502 and Poly (DL-Lactide- co-glycolide) 75:25

Resomer' RG756. Le PLA cristallin peut également être utilisé.  Resomer 'RG756. Crystalline PLA can also be used.

Les caractéristiques et les avantages du produit sont la facilité d' utilisation la seringuabilité du produit; la bio-disponibilité et résorbabilité contrôlée des microsphères de PLGA comme celle du gel vecteur; I' efficacité renforcée des microparticules de PLGA à libération contrôlée quant à leur effet désinfectant comblant, fibrosant etrestructurant au niveau de la ligne amélo-céméntaire le concept naturel du produit par sa formulation d ' origine végétale, minérale  The characteristics and the advantages of the product are the ease of use and the syringability of the product; the bioavailability and controlled resorbability of PLGA microspheres like that of the vector gel; The enhanced effectiveness of PLGA microparticles with controlled release in terms of their filling disinfectant, fibrosing and restructuring effect on the amelo-cemetary line the natural concept of the product by its formulation of vegetable, mineral origin

et bio - génétique excluant tout test d' allergénicité préalable.  and bio - genetics excluding any prior allergenicity test.

Les microsphères de PLGA à libération prolongée incorporées dans un gel de hyaluronates ou de silice colloldale proposent une alternative naturelle aux traitement des parodontopathies avec -2- déchaussement des dents par rapport aux traitements classiques: extraction  The extended-release PLGA microspheres incorporated in a hyaluronate or colloidal silica gel offer a natural alternative to the treatment of periodontal disease with -2- loosening of the teeth compared to conventional treatments: extraction

dentaire, corail, goretex, implant suédois etc... souvent decevants.  dental, coral, goretex, Swedish implant etc ... often disappointing.

Une technique de fabrication des micro-particules à libération prolongée incorporées dans un gel de hyaluronates ou de silice colloïdale a été retenue. Il s ' agit de la technique de coacervation simple par ajout d ' un second polymère au PLGA. Cette méthode consiste à disperser le principe actif retenu: antiseptique ou antibiotique dans une solution de polymère de type PLGA préalablement dissout dans une solution d' acétate d ' éthyle et à introduire un second polymère de type huile de silicone qui fait coacerver le polymère autour du principe actif sous forme d' un enrobage continu jusqu ' à la formation de microsphères. Le coacervat est ensuite dispersé dans un bain d 'heptane afin de durcir les microsphères par extraction du solvant organique et solubilisation de  A technique for manufacturing sustained-release microparticles incorporated in a hyaluronate or colloidal silica gel was chosen. This is the simple coacervation technique by adding a second polymer to PLGA. This method consists in dispersing the active principle retained: antiseptic or antibiotic in a polymer solution of PLGA type previously dissolved in an ethyl acetate solution and in introducing a second polymer of silicone oil type which causes the polymer to coacerve around the active ingredient in the form of a continuous coating until the formation of microspheres. The coacervate is then dispersed in a heptane bath in order to harden the microspheres by extraction of the organic solvent and solubilization of.

I' huile de silicone. Une filtration permet de récupérer les microsphères.  Silicone oil. Filtration makes it possible to recover the microspheres.

La méthode de coacervation simple permet d ' obtenir des micro-  The simple coacervation method provides micro-

sphères bien individualisées de taille comprise entre 20 et 10qum, avec  well individualized spheres of size between 20 and 10qum, with

une valeur moyenne de 50um.an average value of 50um.

Les microsphères de PLGA sont incluses dans un gel physiologique stérile et apyrogène dosé a 0,8% d ' acide hyaluronique de haut poids moléculaire ( sel de sodium). La teneur en hyaluronate de sodium est (2.5.22) ou de silice colloïdale à 5 %. Ce gel est utilisé uniquement comme vecteur afin de maintenir les microsphères en suspension. Il est résorbable en 3 mois environ, ce qui permet aux micospheres de PLGA à libération prolongée de réaliser lentement leur effet restructurant et fibrosant Les différents essais de seringuabilité du produit fini < microsphères de PLGA dans un gel physiologique d'acide hyaluronique à 0.8%) ont déterminé une viscosité suffisante du gel lui permettant de passer dans  The PLGA microspheres are included in a sterile, pyrogen-free physiological gel dosed with 0.8% high molecular weight hyaluronic acid (sodium salt). The sodium hyaluronate content is (2.5.22) or 5% colloidal silica. This gel is used only as a vector in order to keep the microspheres in suspension. It is absorbable in about 3 months, which allows the PLGA micospheres of prolonged release to slowly realize their restructuring and fibrosing effect. The various tests of seringuability of the finished product (PLGA microspheres in a physiological gel of hyaluronic acid at 0.8%) have determined a sufficient viscosity of the gel allowing it to pass into

une aiguille de taille gauge 26 à gauge 30 et de préférence gauge 28.  a needle of size gauge 26 to gauge 30 and preferably gauge 28.

Les microsphères de PLGA peuvent également être incluses dans un gel physiologique stérile et apyrogène dosé à 5% de silice colloïdale Partiellement résorbable à 3 mois la silice colloïdale possède la remarquable  PLGA microspheres can also be included in a sterile and pyrogen-free physiological gel dosed with 5% colloidal silica Partially absorbable at 3 months colloidal silica has the remarkable

propriété - en se déshydratant - de former autour de la ligne amélo-  property - when dehydrating - to form around the amelo-line

cémentaire un véritable ciment protecteur et. partant, de bloquer toutes migrations bactériennes au niveau du sillon gingival dont elle assure la  cementitious a real protective cement and. therefore, to block all bacterial migrations at the level of the gingival groove which it ensures the

reconstruction.reconstruction.

Les deux gels décrits plus haut garderont leur bonne viscosité si le pourcentage de microsphères de PLGA dans les gels est de 5% à 40% et de préférence de 7% à 25% Le produit fini a été testé sur le lapin et le rat afin de s ' assurer de la non toxicité du produit et également afin de vérifier les périodes de résorbabilité du gel ( 3 mois) et des microsphères ( 6 mois à 1 an) -3- le PLGA dans une solution d ' acétate d' éthyle et à introduire un second polymère de type huile de silicone fait coacerver le polymère sous forme de micosphères. Le coacervat est ensuite dipersé dans un bain d 'heptane afin de durcir les microsphères par extraction du solvant organique et solubilisation de I ' huile de silicone. Une filtration permet de récupérer les microsphères  The two gels described above will keep their good viscosity if the percentage of PLGA microspheres in the gels is from 5% to 40% and preferably from 7% to 25% The finished product has been tested on rabbits and rats in order to ensure the non-toxicity of the product and also in order to verify the periods of resorbability of the gel (3 months) and of the microspheres (6 months to 1 year) -3- the PLGA in a solution of ethyl acetate and at introducing a second polymer of silicone oil type makes the polymer coacerve in the form of micospheres. The coacervate is then dipers in a heptane bath in order to harden the microspheres by extraction of the organic solvent and solubilization of the silicone oil. Filtration to recover microspheres

La méthode de coacervation simple permet d ' obtenir des micro-  The simple coacervation method provides micro-

sphères bien individualisées de taille comprise entre 20 et 100jum. avec  well individualized spheres of size between 20 and 100jum. with

une valeur moyenne de 50um -an average value of 50um -

Les microsphères de PLGA sont incluses dans un gel physiologique stérile et apyrogène dosé a 0,8% d ' acide hyaluronique de haut poids moléculaire ( sel de sodium). La teneur en hyaluronate de sodium est (2.5.22) - Ce gel est utilisé uniquement comme vecteur afin de maintenir les microsphères en suspension. Il est résorbable en 3 mois environ. ce qui permet aux micosphères de PLGA à libération prolongée de réaliser  The PLGA microspheres are included in a sterile, pyrogen-free physiological gel dosed with 0.8% high molecular weight hyaluronic acid (sodium salt). The sodium hyaluronate content is (2.5.22) - This gel is used only as a vector to keep the microspheres in suspension. It is absorbable in about 3 months. which allows the extended release PLGA micospheres to achieve

lentement leur effet restructurant et fibrosant.  slowly their restructuring and fibrosing effect.

Les différents essais de seringuabilité du produit fini ( microsphères de PLGA dans un gel physiologique d'acide hyaluronique à 0.8%) ont déterminé une viscosité suffisante du gel lui permettant de passer dans  The various tests for syringability of the finished product (PLGA microspheres in a physiological gel of hyaluronic acid at 0.8%) determined a sufficient viscosity of the gel allowing it to pass into

une aiguille de taille gauge 26 à gauge 30 et de préférence gauge 28.  a needle of size gauge 26 to gauge 30 and preferably gauge 28.

Les microsphères de PLGA peuvent également être incluses dans un  PLGA microspheres can also be included in a

gel physiologique sterile et apyrogène dosé à 5% de silice cololdale.  sterile and pyrogen-free physiological gel dosed with 5% cololdal silica.

Partiellement résorbable à 3 mois la silice cololdale possède la remarquable  Partially absorbable at 3 months, colloidal silica has the remarkable

propriété - en se déshydratant - de former autour de la ligne amélo-  property - when dehydrating - to form around the amelo-line

cémentaire un véritable ciment protecteur et, partant, de bloquer toutes migrations bactériennes au niveau du sillon gingival dont elle assure la reconstruction Les deux gels decrits plus haut garderont leur bonne viscosité si le pourcentage de microsphères de PLGA dans les gels est de 5% à 40% et  cementitious a real protective cement and, consequently, to block all bacterial migrations at the level of the gingival groove of which it ensures the reconstruction. The two gels described above will keep their good viscosity if the percentage of PLGA microspheres in the gels is from 5% to 40 % and

de préférence de 7% à 25%.preferably from 7% to 25%.

Le produit fini a été testé sur le lapin et le rat afin de s 'assurer de la non toxicité du produit et également afin de vérifier les périodes de  The finished product has been tested on rabbits and rats to ensure the non-toxicity of the product and also to check the periods of

résorbabilité du gel < 3 mois) et des microsphères ( 6 mois à 1 an).  resorbability of the gel <3 months) and of the microspheres (6 months to 1 year).

- 4 -- 4 -

Claims (6)

REVENDICATIONS 1) Implant injectable destiné à traiter les parodontopathies ponctuelles ou chroniques: poches parodontales ou pyorées alvéo-dentaires notamment, permettant la reconstruction du sillon gingival et de l'attache épithéliale et5 la mise en place - par son effet fibrosant - d'un faisceau de fibres secondaires en soutien du ligament parodontal et de la ligne amélo- cémentaire, caractérisé en ce qu'il est constitué de microsphères bio- résorbables de polymères de type copolymère  1) Injectable implant intended to treat punctual or chronic periodontal diseases: periodontal pockets or alveodental pyoreas in particular, allowing the reconstruction of the gingival groove and the epithelial attachment and5 the establishment - by its fibrosing effect - of a bundle of secondary fibers in support of the periodontal ligament and the amelementary line, characterized in that it consists of bio-absorbable microspheres of copolymer type polymers d'acide lactique-coglycolique (PGLA): Poly (D,L - Lactide-  lactic-coglycolic acid (PGLA): Poly (D, L - Lactide- coglycolide) Resomer RG 502 et RG 756 en suspension dans un gel physiologique à 0,8% d'acide hyaluronique ou dans un gel  coglycolide) Resomer RG 502 and RG 756 suspended in a physiological gel containing 0.8% hyaluronic acid or in a gel physiologique à 5% de silice colloïdale.  physiological with 5% colloidal silica. 2) Implant selon la revendication 1 caractérisé en ce que les microsphères sont constituées de polymères biodégradables de  2) Implant according to claim 1 characterized in that the microspheres consist of biodegradable polymers of type copolymère d'acide lactique-coglycolique (PGLA) coacervé.  coacervated lactic-coglycolic acid copolymer (PGLA) type. 3) Implant selon la revendication 1 caractérisé en ce que la proportion de microsphères dans le gel est de 5% à 40% et de  3) Implant according to claim 1 characterized in that the proportion of microspheres in the gel is 5% to 40% and préférence de 7% à 25%.preferably from 7% to 25%. 4) Implant selon la revendication 1 caractérisé en ce que les microsphères sont bio-résorbables en une période de 6 mois à 1 an. ) Implant selon la revendication 1 caractérisé en ce que le gel vecteur inclut principalement comme agent de gélification  4) Implant according to claim 1 characterized in that the microspheres are bio-absorbable in a period of 6 months to 1 year. ) Implant according to claim 1 characterized in that the carrier gel mainly includes as a gelling agent le hyaluronate de sodium titré à 0,8%.  sodium hyaluronate titrated at 0.8%. 6) Implant selon la revendication 1 caractérisé en ce que la taille des microsphères soit comprise entre 20mm et 100im avec une valeur moyenne de 50m permettant une bonne seringuabilité du produit fini et un passage dans une aiguille  6) Implant according to claim 1 characterized in that the size of the microspheres is between 20mm and 100im with an average value of 50m allowing good syringability of the finished product and passage through a needle de taille gauge 26 à gauge 30 et de préférence gauge 28.  from gauge 26 to gauge 30 and preferably gauge 28. 7) Implant selon la revendication 1 caractérisé en ce que les microsphères contiennent un ou plusieurs principes actifs de type antiseptique: hexetidine, acide propionique, chlorhexidine, hexamidine ou de type antibiotique: macrolides, spiramicine,  7) Implant according to claim 1 characterized in that the microspheres contain one or more active principles of antiseptic type: hexetidine, propionic acid, chlorhexidine, hexamidine or of antibiotic type: macrolides, spiramicin, cycline, metronidazole.cyclin, metronidazole.
FR9806415A 1998-05-20 1998-05-20 Implants for sub-gingival injection comprising bio-resorbable microspheres containing an antiseptic or antibiotic Withdrawn FR2778847A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR9806415A FR2778847A1 (en) 1998-05-20 1998-05-20 Implants for sub-gingival injection comprising bio-resorbable microspheres containing an antiseptic or antibiotic

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9806415A FR2778847A1 (en) 1998-05-20 1998-05-20 Implants for sub-gingival injection comprising bio-resorbable microspheres containing an antiseptic or antibiotic

Publications (1)

Publication Number Publication Date
FR2778847A1 true FR2778847A1 (en) 1999-11-26

Family

ID=9526575

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9806415A Withdrawn FR2778847A1 (en) 1998-05-20 1998-05-20 Implants for sub-gingival injection comprising bio-resorbable microspheres containing an antiseptic or antibiotic

Country Status (1)

Country Link
FR (1) FR2778847A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001028591A2 (en) * 1999-10-15 2001-04-26 Genentech, Inc. Injection vehicle for polymer-based formulations
FR2840193A1 (en) * 2002-05-31 2003-12-05 Textile Hi Tec GASTRIC BAND
US6716251B1 (en) * 1997-06-13 2004-04-06 Aventis Pharmaceuticals Holdings, Inc. Implant for subcutaneous or intradermal injection
US7651703B2 (en) 1999-10-15 2010-01-26 Genentech, Inc. Injection vehicle for polymer-based formulations
RU2613299C1 (en) * 2015-12-21 2017-03-15 Федеральное государственное автономное образовательное учреждение высшего образования "Крымский федеральный университет имени В.И. Вернадского" Method for treating diseases of parodontium, periodontium and oral cavity mucosa
CN110327497A (en) * 2019-07-31 2019-10-15 易浦润（上海）生物技术有限公司 A kind of injection gel and preparation method thereof containing microballoon
WO2020245074A1 (en) * 2019-06-01 2020-12-10 Lupin Holdings B.V. Monodisperse resorbable polyester polymer compositions

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0263490A2 (en) * 1986-10-07 1988-04-13 Chugai Seiyaku Kabushiki Kaisha Sustained-release particulate preparation and process for preparing the same
US5059123A (en) * 1990-05-14 1991-10-22 Jernberg Gary R Periodontal barrier and method for aiding periodontal tissue regeneration
JPH0499725A (en) * 1990-08-15 1992-03-31 Sunstar Inc Drug for promoting reproduction of periodontium
JPH0549692A (en) * 1991-08-23 1993-03-02 Taki Chem Co Ltd Blank material for treating paradental disease
EP0633020A1 (en) * 1993-07-05 1995-01-11 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
EP0784985A1 (en) * 1994-09-30 1997-07-23 Yamanouchi Pharmaceutical Co. Ltd. Osteoplastic graft
WO1997044016A1 (en) * 1996-05-23 1997-11-27 Samyang Corporation Locally administrable, biodegradable and sustained-release pharmaceutical composition for periodontitis and process for preparation thereof
WO1998056431A1 (en) * 1997-06-13 1998-12-17 Biopharmex Holding S.A. Implant for subcutaneous or intradermal injection

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0263490A2 (en) * 1986-10-07 1988-04-13 Chugai Seiyaku Kabushiki Kaisha Sustained-release particulate preparation and process for preparing the same
US5059123A (en) * 1990-05-14 1991-10-22 Jernberg Gary R Periodontal barrier and method for aiding periodontal tissue regeneration
JPH0499725A (en) * 1990-08-15 1992-03-31 Sunstar Inc Drug for promoting reproduction of periodontium
JPH0549692A (en) * 1991-08-23 1993-03-02 Taki Chem Co Ltd Blank material for treating paradental disease
EP0633020A1 (en) * 1993-07-05 1995-01-11 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
EP0784985A1 (en) * 1994-09-30 1997-07-23 Yamanouchi Pharmaceutical Co. Ltd. Osteoplastic graft
WO1997044016A1 (en) * 1996-05-23 1997-11-27 Samyang Corporation Locally administrable, biodegradable and sustained-release pharmaceutical composition for periodontitis and process for preparation thereof
WO1998056431A1 (en) * 1997-06-13 1998-12-17 Biopharmex Holding S.A. Implant for subcutaneous or intradermal injection

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 118, no. 24, 14 June 1993, Columbus, Ohio, US; abstract no. 241020, YOKOTA M. ET AL: "Polymers of lactic acid and glycolic acid for periodontosis treatment" XP002091151 *
DATABASE WPI Section Ch Week 9219, Derwent World Patents Index; Class A05, AN 92-157313, XP002091152 *
DATABASE WPI Section Ch Week 9314, Derwent World Patents Index; Class A23, AN 93-111926, XP002091153 *
PATENT ABSTRACTS OF JAPAN vol. 016, no. 338 (C - 0965) 22 July 1992 (1992-07-22) *
PATENT ABSTRACTS OF JAPAN vol. 017, no. 355 (C - 1079) 6 July 1993 (1993-07-06) *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716251B1 (en) * 1997-06-13 2004-04-06 Aventis Pharmaceuticals Holdings, Inc. Implant for subcutaneous or intradermal injection
US7731758B2 (en) 1997-06-13 2010-06-08 Aventis Pharmaceuticals Holdings, Inc. Implant for subcutaneous or intradermal injection
US8414657B2 (en) 1997-06-13 2013-04-09 Valeant International Bermuda Method for subcutaneous or intradermal injection
WO2001028591A2 (en) * 1999-10-15 2001-04-26 Genentech, Inc. Injection vehicle for polymer-based formulations
WO2001028591A3 (en) * 1999-10-15 2002-03-07 Genentech Inc Injection vehicle for polymer-based formulations
US7582311B1 (en) 1999-10-15 2009-09-01 Genentech, Inc. Injection vehicle for polymer-based formulations
US7651703B2 (en) 1999-10-15 2010-01-26 Genentech, Inc. Injection vehicle for polymer-based formulations
FR2840193A1 (en) * 2002-05-31 2003-12-05 Textile Hi Tec GASTRIC BAND
WO2003101352A1 (en) * 2002-05-31 2003-12-11 Textile Hi Tec Gastric ring
RU2613299C1 (en) * 2015-12-21 2017-03-15 Федеральное государственное автономное образовательное учреждение высшего образования "Крымский федеральный университет имени В.И. Вернадского" Method for treating diseases of parodontium, periodontium and oral cavity mucosa
WO2020245074A1 (en) * 2019-06-01 2020-12-10 Lupin Holdings B.V. Monodisperse resorbable polyester polymer compositions
CN110327497A (en) * 2019-07-31 2019-10-15 易浦润（上海）生物技术有限公司 A kind of injection gel and preparation method thereof containing microballoon

Similar Documents

Publication Publication Date Title
Sah et al. Potential of chitosan-based carrier for periodontal drug delivery
Divband et al. Bioactive chitosan biguanidine-based injectable hydrogels as a novel BMP-2 and VEGF carrier for osteogenesis of dental pulp stem cells
Cao et al. Bone regeneration using photocrosslinked hydrogel incorporating rhBMP-2 loaded 2-N, 6-O-sulfated chitosan nanoparticles
Perugini et al. Periodontal delivery of ipriflavone: new chitosan/PLGA film delivery system for a lipophilic drug
Wang et al. A tunable and injectable local drug delivery system for personalized periodontal application
DE69733889T3 (en) SOLUBLE OXIDES FOR BIOLOGICAL APPLICATIONS
Lan et al. Controlled release of metronidazole from composite poly-ε-caprolactone/alginate (PCL/alginate) rings for dental implants
US20210308337A1 (en) Compositions and methods for enhancing healing and regeneration of bone and soft tissue
Veríssimo et al. Polyanionic collagen membranes for guided tissue regeneration: Effect of progressive glutaraldehyde cross-linking on biocompatibility and degradation
JP2685353B2 (en) Biodegradable system for periodontal tissue regeneration
JP2977724B2 (en) Complex substance for periodontal disease treatment
US20160235889A1 (en) Silk/platelet composition and use thereof
CN105561384A (en) Platelet-derived growth factor compositions and methods of use thereof
JP2005529879A (en) New biomaterials, their manufacture and use
Wan et al. Investigating a new drug delivery nano composite membrane system based on PVA/PCL and PVA/HA (PEG) for the controlled release of biopharmaceuticals for bone infections
US20190255181A1 (en) Silk Powder Compaction for Production of Constructs with High Mechanical Strength and Stiffness
Doǧan et al. Controlled release of EGF and bFGF from dextran hydrogels in vitro and in vivo
Bhattacharjee et al. Potential of non-mulberry silk protein fibroin blended and grafted poly (Є-caprolactone) nanofibrous matrices for in vivo bone regeneration
e Silva et al. Hyaluronic acid on collagen membranes: An experimental study in rats
FR2778847A1 (en) Implants for sub-gingival injection comprising bio-resorbable microspheres containing an antiseptic or antibiotic
Abdo et al. Underestimated microbial infection of resorbable membranes on guided regeneration
Abdelrasoul et al. Regeneration of critical‐sized grade II furcation using a novel injectable melatonin‐loaded scaffold
US20230073125A1 (en) Periodontal micropatch and uses thereof
Küçüktürkmen et al. Development of zoledronic acid containing biomaterials for enhanced guided bone regeneration
da Silveira et al. Biopolymer membranes for dentistry applications

Legal Events

Date Code Title Description
TP Transmission of property
ST Notification of lapse